A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma.

Trial Profile

A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2013

At a glance

  • Drugs IPH 1101 (Primary) ; Aldesleukin; Dacarbazine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
    • 26 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top